INTRODUCTION: The utility of blood-based Alzheimer's disease (AD) biomarkers in predicting clinical trajectories remains uncertain. METHODS: We assessed the diagnostic and prognostic performance of p-tau181, p-tau217, GFAP, and NfL in a large memory-clinic cohort (n=3,645) with comprehensive baseline clinical evaluatio...
Xue-Mei Zeng, Nicholas Heaton, Rebecca A. Deek et al.· medRxiv· 0 citations
Objective: Late-life depression (LLD) increases dementia risk, emphasizing the potential and importance of lifestyle interventions to support cognition. However, no biomarker-based models currently exist to predict their effectiveness. We examined whether plasma Alzheimer’s disease and related dementia (ADRD) biomark...
Keeley M. Scullin, A. P. Costa, Amrita Sahu et al.· Archives of Clinical Neurops...· 0 citations
Background: Alzheimer's disease (AD) is a complex neurodegenerative disorder strongly influenced by genetic factors, with apolipoprotein E (APOE) {epsilon}4 allele being the most established risk variant. Although DNA-based genotyping remains standard, plasma proteotyping may provide scalable, isoform-specific alternat...
Ru-Yu Shi, L. Choity, M. Farinas et al.· medRxiv· 0 citations